NATIONAL ASSOCIATION FOR CONTINUING EDUCATION

300 Northwest 70th Avenues, Suite 102 • Plantation, Florida 33317
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

Challenges in Pulmonary and Critical Care: 2012

December 1, 2012
Cleveland Clinic Florida
Weston, FL

Course Director
Franck Rahaghi, MD, MHS, FCCP

Program Evaluation
December 26, 2012

In December 2012, the National Association for Continuing Education (NACE) sponsored a CME activity, *Challenges in Pulmonary and Critical: 2012*, in Weston, FL.

This educational activity was designed to provide an update in the prevention, diagnosis, and management of pulmonary disease to pulmonologists, hospitalists, and other health care providers who treat patients with pulmonary diseases. Current findings in pulmonary research in such topics as bronchiscopy, COPD, alpha-1 antitrypsin deficiency, sedation in the ICU, idiopathic pulmonary fibrosis, chronic cough, pulmonary arterial hypertension, and asthma were presented.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

One hundred sixty five healthcare practitioners registered to attend *Challenges in Pulmonary and Critical: 2012* in Weston, FL. One hundred twenty two healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. One hundred twelve completed forms were received. The data collected is displayed in this report.

CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

* This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of University of Massachusetts Medical School and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The University of Massachusetts Medical School designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	63	56.25	56.76
DO	5	4.46	4.50
NP	9	8.04	8.11
PA	5	4.46	4.50
RN	8	7.14	7.21
Other	21	18.75	18.92
Total Valid	111	99.11	100.00
Total Missing	1	0.89	
Total	112	100.00	



What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	39	34.82	36.79
Endocrinology	0	0.00	0.00
Rheumatology	3	2.68	2.83
Pulmonology	42	37.50	39.62
Cardiology	3	2.68	2.83
Gastroenterology	0	0.00	0.00
OB/GYN	0	0.00	0.00
Other	19	16.96	17.92
Total Valid	106	94.64	100.00
Total Missing	6	5.36	
Total	112	100.00	



Upon completion of this activity, I can now - Define the methodology and advantages of navigational bronchoscopy; Describe bronchial thermoplasty and review the data for the procedure; Define patient selection for the procedures:

Label	Frequency	Percent	Valid Percent
Yes	91	81.25	85.05
Somewhat	16	14.29	14.95
Not at all	0	0.00	0.00
Total Valid	107	95.54	100.00
Total Missing	5	4.46	
Total	112	100.00	



Upon completion of this activity, I can now - Explain the pathogenesis and diagnosis of COPD; Discuss findings of recent trials and evidence-based treatment options for COPD; Discuss new GOLD guidelines; Explore new and evolving treatments for COPD:

Label	Frequency	Percent	Valid Percent
Yes	104	92.86	96.30
Somewhat	4	3.57	3.70
Not at all	0	0.00	0.00
Total Valid	108	96.43	100.00
Total Missing	4	3.57	
Total	112	100.00	



Upon completion of this activity, I can now - Explain the etiology of alpha-1 antitrypsin deficiency (AATD); Discuss how to change your office flow to incorporate testing for AATD and utilization of ancillary staff and the pulmonary function lab; Explain treatments for AATD:

Label	Frequency	Percent	Valid Percent
Yes	96	85.71	87.27
Somewhat	14	12.50	12.73
Not at all	0	0.00	0.00
Total Valid	110	98.21	100.00
Total Missing	2	1.79	
Total	112	100.00	



Upon completion of this activity, I can now - Discuss indications for sedation in the ICU; Assess adequacy of sedation in the ICU; Identify strategies for administration of sedation in the ICU:

Label	Frequency	Percent	Valid Percent
Yes	84	75.00	84.85
Somewhat	14	12.50	14.14
Not at all	1	0.89	1.01
Total Valid	99	88.39	100.00
Total Missing	13	11.61	
Total	112	100.00	



Upon completion of this activity, I can now - Describe the state-of-the-art approach to diagnosing idiopathic pulmonary fibrosis (IPF) from among a range of diffuse parenchymal lung disorders; Define prognostic features for individual IPF patients; Apply appropriate pharmacotherapeutic options for individual IPF patients while having a gneral understanding of the options under intense investigation; Recognize the role of available nonpharmacological therapies including pulmonary rehabilitation, oxygen supplementation and lung transplantation in IPF management:

Label	Frequency	Percent	Valid Percent
Yes	85	75.89	80.19
Somewhat	21	18.75	19.81
Not at all	0	0.00	0.00
Total Valid	106	94.64	100.00
Total Missing	6	5.36	
Total	112	100.00	



Upon completion of this activity, I can now - Explain the differential diagnosis of patients with chronic cough; Descibe the workup of patients suspected of having chronic cough; Discuss the use of FeNO, laryngoscopy, pH catheter and spirometry in the initial assessment of patients with chronic cough; Identify therapeutic options in patients with chronic cough:

Label	Frequency	Percent	Valid Percent
Yes	89	79.46	91.75
Somewhat	8	7.14	8.25
Not at all	0	0.00	0.00
Total Valid	97	86.61	100.00
Total Missing	15	13.39	
Total	112	100.00	



Upon completion of this activity, I can now - Explain the pathophysiology of pulmonary arterial hypertension (PAH); Discuss the workup of patients suspected of having PAH; Discuss criteria for diagnosis and accurate assessment of disease severity in patients with PAH; List therapeutic options in the management of patients with PAH and discuss effective use of targeted treatment options for PAH; Discuss the pipeline of new PAH medications:

Label	Frequency	Percent	Valid Percent
Yes	93	83.04	84.55
Somewhat	17	15.18	15.45
Not at all	0	0.00	0.00
Total Valid	110	98.21	100.00
Total Missing	2	1.79	
Total	112	100.00	



Upon completion of this activity, I can now - Explain the philosophy of the new asthma recommendation; Discuss utilization of individualized therapy for patients with asthma; Examine novel asthma therapies and future directions:

Label	Frequency	Percent	Valid Percent
Yes	95	84.82	90.48
Somewhat	10	8.93	9.52
Not at all	0	0.00	0.00
Total Valid	105	93.75	100.00
Total Missing	7	6.25	
Total	112	100.00	



Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	88	78.57	78.57
Very Good	24	21.43	21.43
Good	0	0.00	0.00
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	112	100.00	100.00



Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	82	73.21	73.21
Agree	28	25.00	25.00
Neutral	2	1.79	1.79
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	112	100.00	100.00



Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid Percent
Strongly Agree	86	76.79	76.79
Agree	24	21.43	21.43
Neutral	1	0.89	0.89
Disagree	1	0.89	0.89
Strongly Disagree	0	0.00	0.00
Total Valid	112	100.00	100.00

As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	82	73.21	73.21
Agree	28	25.00	25.00
Neutral	1	0.89	0.89
Disagree	1	0.89	0.89
Strongly Disagree	0	0.00	0.00
Total Valid	112	100.00	100.00



How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	70	62.50	63.64
Somewhat likely	23	20.54	20.91
Unlikely	2	1.79	1.82
Not applicable	15	13.39	13.64
Total Valid	110	98.21	100.00
Total Missing	2	1.79	
Total	112	100.00	



When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	56	50.00	52.83
1-3 months	17	15.18	16.04
4-6 months	6	5.36	5.66
Not applicable	27	24.11	25.47
Total Valid	106	94.64	100.00
Total Missing	6	5.36	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Eduardo Oliveira, MD (Broncho):

Label	Frequency	Percent	Valid Percent
Excellent	91	81.25	81.98
Very Good	19	16.96	17.12
Good	1	0.89	0.90
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	111	99.11	100.00
Total Missing	1	0.89	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Charlie Strange, MD (COPD):

Label	Frequency	Percent	Valid Percent
Excellent	101	90.18	90.99
Very Good	9	8.04	8.11
Good	1	0.89	0.90
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	111	99.11	100.00
Total Missing	1	0.89	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (AATD):

Label	Frequency	Percent	Valid Percent
Excellent	93	83.04	84.55
Very Good	15	13.39	13.64
Good	2	1.79	1.82
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	110	98.21	100.00
Total Missing	2	1.79	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Ioana Preston, MD (PAH):

Label	Frequency	Percent	Valid Percent
Excellent	89	79.46	82.41
Very Good	12	10.71	11.11
Good	7	6.25	6.48
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	108	96.43	100.00
Total Missing	4	3.57	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Robert Kaner, MD (IPF):

Label	Frequency	Percent	Valid Percent
Excellent	79	70.54	78.22
Very Good	21	18.75	20.79
Good	1	0.89	0.99
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	101	90.18	100.00
Total Missing	11	9.82	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Gustavo Ferrer, MD (Chron Cough):

Label	Frequency	Percent	Valid Percent
Excellent	79	70.54	86.81
Very Good	10	8.93	10.99
Good	2	1.79	2.20
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	91	81.25	100.00
Total Missing	21	18.75	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Jinesh Mehta, MD (Sedation):

Label	Frequency	Percent	Valid Percent
Excellent	72	64.29	77.42
Very Good	16	14.29	17.20
Good	4	3.57	4.30
Fair	1	0.89	1.08
Unsatisfactory	0	0.00	0.00
Total Valid	93	83.04	100.00
Total Missing	19	16.96	
Total	112	100.00	



In terms of delivery of the presentation, please rate the effectiveness of the speaker: Raed A. Dweik, MD (Asthma):

Label	Frequency	Percent	Valid Percent
Excellent	84	75.00	83.17
Very Good	15	13.39	14.85
Good	2	1.79	1.98
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	101	90.18	100.00
Total Missing	11	9.82	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Eduardo Oliveira, MD (Broncho):

Label	Frequency	Percent	Valid Percent
Excellent	97	86.61	88.99
Very Good	11	9.82	10.09
Good	1	0.89	0.92
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	109	97.32	100.00
Total Missing	3	2.68	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Charlie Strange, MD (COPD):

Label	Frequency	Percent	Valid Percent
Excellent	101	90.18	92.66
Very Good	8	7.14	7.34
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	109	97.32	100.00
Total Missing	3	2.68	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (AATD):

Label	Frequency	Percent	Valid Percent
Excellent	100	89.29	90.91
Very Good	9	8.04	8.18
Good	1	0.89	0.91
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	110	98.21	100.00
Total Missing	2	1.79	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Ioana Preston, MD (PAH):

Label	Frequency	Percent	Valid Percent
Excellent	99	88.39	90.00
Very Good	10	8.93	9.09
Good	1	0.89	0.91
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	110	98.21	100.00
Total Missing	2	1.79	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert Kaner, MD (IPF):

Label	Frequency	Percent	Valid Percent
Excellent	91	81.25	89.22
Very Good	10	8.93	9.80
Good	1	0.89	0.98
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	102	91.07	100.00
Total Missing	10	8.93	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Gustavo Ferrer, MD (Chron Cough):

Label	Frequency	Percent	Valid Percent
Excellent	85	75.89	90.43
Very Good	8	7.14	8.51
Good	1	0.89	1.06
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	94	83.93	100.00
Total Missing	18	16.07	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Jinesh Mehta, MD (Sedation):

Label	Frequency	Percent	Valid Percent
Excellent	83	74.11	87.37
Very Good	10	8.93	10.53
Good	2	1.79	2.11
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	95	84.82	100.00
Total Missing	17	15.18	
Total	112	100.00	



To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Raed A. Dweik, MD (Asthma):

Label	Frequency	Percent	Valid Percent
Excellent	91	81.25	90.10
Very Good	10	8.93	9.90
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	101	90.18	100.00
Total Missing	11	9.82	
Total	112	100.00	



Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid Percent
Topics covered	97	86.61	86.61
Location/ease of access	65	58.04	58.04
Faculty	48	42.86	42.86
Earn CME credits	75	66.96	66.96
Total Valid	112	100.00	100.00



Future CE activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	65	58.04	59.09
Agree	37	33.04	33.64
Neutral	8	7.14	7.27
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	110	98.21	100.00
Total Missing	2	1.79	
Total	112	100.00	



What is your professional degree?

Comment
RRT
RRT
RRT
RRT
RRT
LPN
RRT
RRT
LPN
LPN
RRT
RRT
RRT
RRT
RRT
RRT
RRT
MBA
RT
RRT
RRT

What is your specialty?

Comment
Respiratory
Cardiopulmoanry
Dermatology
Pathology
Respiratory
Respiratory
Hematology
Psychiatry
CRT
Respiratory
Respiratory
IMM
Surgery
Dermatology
Respiratory
General Practice

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
Implementing new opinions and established recommendations.
Importance of specification of diagnosis. Accurate treatment. Involvement of medical team.
Increase knowledge of the challenge in pulmonary and critical care points.
Strategies in newer patient care algorithm.
Missing more of the available diagnostic tools in the evaluation of several pulmonary diseases.
Treat pulmonary HTN
More comprehensive testing for more accurate diagnosis for appropriate therapies.
Request, be open to reconsider. Be positive. gene therapy = progress. Retired, talk about them at office.
Ability to better diagnosis Pulmonary fibrosis. More efficient treatment of Asthma.
Describe echo finding as "elevated PA pressure" rather than "pulmonary hypertension"
Better screening for COPD, dx + tx Pulmonary HT
Pain control classification of asthma PFT
Increase vigilance, increase aggressive treatment
COPD new treatment horizons/Alpha-1 of antitrypsm deficiency update, evolution of Pulmonary hypertension/new directions in treatment of asthma and chronic cough/sedation in ICU update.
1. Change approach in considering testing for alpha one antritrypsin deficiency 2. Treatment modalities COPD like exercise training program make more emphasis
Use the methacholine challenge test
Apply new ways dx + tx
Start testing for AAT more
1. Early connect dx 2. good referral for MD 3. pt education and family education
Using FENU for Asthma
Screen more for antitrypsin deficiency
Better assessment to improve quality of care and to reduce unnecessary procedures.
Approach to pulmonary hypertension. Use of NO monitoram in asthma.
Could lead to improved patient care and safety review guidelines for future reference.
Early dx AAT deficiency, accurate dx of IPF
Use in RN protocols
Learned about thermoplasty and it's indications.
New gold guidelines of COPD, increased screening for AAT.
Improve early diagnostic procedures. Increase and implement physician-patient interaction.
Bronchial thermoplasty - electromagnetic navigation bronchoscopy. New directions in treatment of asthma.
We are limited to what we can do in the jail system.
1. More aggressive in screening of antitrypsin pts 2. In chronic persistent asthma trial of thermoplasty 3. In general screening pts for COPD
ENB, thermoplasty
Check alpha-1 levels more frequently, follow steps for asthma, consider use of bronchial thermoplasty
Test pt regardless of clinical study data
Implementation of better PAH therapies
Utilization/referral for EMB for selected cases, better handling of PAH cases

Comment
Decisions for patients with small nodules of the lung and need of navigational bronchoscopy, benefits for bronchial thermoplasty for asthma patients with mid-severe.
Increased screening
This has helped me to ask more specific questions to better care for the patients.
Asthma control test, alpha-1 screening level plus either phenotype or genotype.
FeNO measurement, invasive bronchoscopy
Better understanding of disease process and treatments available.
Appropriate evaluation, appropriate diagnosis, appropriate treatment
Included all the latest changes in the field of topics discussed today in my practice.
New asthma education recommendations for monitoring disease. Increased awareness of COPD gold guidelines
Sedation on ICU (+choices on medication), recommendation, ILD treatment of dx COPD-subtypes, asthma therapy
New ways of diagnosis and treatment
Increase testing
Increase AATD testing. Better diagnostic strategies in dx of IPF. Use of FENO in asthma
Testing - differential diagnosis. Seeing the whole picture & pt care
Better understanding of PFT's- will test earlier. Test for AAT def. Much better understanding of IPF.
ENB, thermoplasty
I'll do more testing
Testing any COPD patient in Pulm Rehab I suspect may have Apha-1 deficiency, which includes all my COPD patients!
Liked the current updates
Use FENO in asthma management. Chronic cough evaluation.
More aggressive treatment for patients with PAH, if they have a severe disease go ahead with IV therapy

What topics would you like to see offered as CE activities in the future?

Comment
Emphasis preventive measures for a better quality of life. Hypertension treatment (update) HCVD, cardiovascular health
Peripheral artery disease. Lymphoma. Venous insufficiency.
Pain management
mother cell
Ventilator management
Thyroid and Pancreatic disease
Endocrinology; G.I. Conditions Inflammatory.
Topics on health prevention strategies/neuromuscular diseases/ALS/MS/Parkinson's
Sepsis, mechanical ventilation, ARDS
Aesthetics
Mechanical ventilation
Liver disease
Ventilators, testing for cancer (gene)

Comment
Prostate cancer management/treatment of post-operative urinary incontinence
ARDS
Diag. tests
Lung cancer staging, screening
genetic disease
Dermatology for primary care
ARDS
Lung disease, environmental systemic
Rheumatology, reproductive health
Immune suppressive or modulators pharmacology & pain mgmt with pathophysiology
Critical care topics
Palliative care integrated to pulmonary & critical care medicine
Infections, epidemiology, oncology
Depression, IBS, abdominal pain, colon cancer
Diabetes, HTN
Hematology
Chronis sinusitis, allergic rhinitis
IPF, COPD, asthma
Lung transplants
Any related to I.M.
Cystic Fibrosis
Neurosurgery, Rad/Oncology
Rheumatological diseases, SLE, lupus nephritis, wound care
Any in medicine
Different subjects, more critical care topics next year
Lipid management, Cardiovascular disease
HTN- Neurologic problems, infectious diseases
Schizophrenia, bipolar disorder
Neurology for Primary Care- tremor, dementia, Parkinson's
Hepatology - cirrhosis, viral hepatitis
Pediatric challenges
Common ENT disorders
Diabetes, dialysis

Additional comments:

Comment
Thank you for all the time and effort on this activity
Excellent presentation by Dr. Strange
Excellent
Good job
2 days NACE
Thank you
Thank you!
Continue providing such excellent conferences
Dr. Jinesh Mehta did a nice presentation
Excellent
It's great that this is free!
Excellent CME
Excellent course
Ok
Would like to receive notice of future offerings
Excellent presentations on all topics
Please add more tables
Good program. Made me realize the incidence and prevalence of lung disease is much more than medical professionals think
Wonderful experience
Great conference
Very well organized
Thank you
More time for questions
Room was very cold
Very good
Thank you
Excellent program
Great program. Thank you for the invitation. Very nice syllabus
Interactive presentations enhance learning

Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	2.58	3.61	1.15	1.04	1.13	1.16	1.20
Variance	4.21	6.14	0.13	0.04	0.11	0.16	0.16
Standard Deviation	2.05	2.48	0.36	0.19	0.33	0.40	0.40
Standard Error	0.19	0.24	0.03	0.02	0.03	0.04	0.04
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	6.00	8.00	2.00	2.00	2.00	3.00	2.00
Median	1.00	4.00	1.00	1.00	1.00	1.00	1.00
Range	5.00	7.00	1.00	1.00	1.00	2.00	1.00

	Learning Objectives6	Learning Objectives7	Learning Objectives8	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care
Mean	1.08	1.15	1.10	1.21	1.29	1.26	1.29
Variance	0.08	0.13	0.09	0.17	0.24	0.27	0.28
Standard Deviation	0.28	0.36	0.29	0.41	0.49	0.52	0.53
Standard Error	0.03	0.03	0.03	0.04	0.05	0.05	0.05
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	2.00	2.00	2.00	2.00	3.00	4.00	4.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	1.00	1.00	1.00	1.00	2.00	3.00	3.00

	Make Changes	Implement New Strategies	Eduardo Oliveira MD {Broncho}	Charlie Strange MD {COPD}	Franck Rahaghi MD {AATD}	Ioana Preston MD {PAH}	Robert Kaner MD {IPF}
Mean	1.65	2.04	4.81	4.90	4.83	4.76	4.77
Variance	1.09	1.62	0.17	0.11	0.18	0.32	0.20
Standard Deviation	1.04	1.27	0.42	0.33	0.43	0.56	0.44
Standard Error	0.10	0.12	0.04	0.03	0.04	0.05	0.04
Minimum	1.00	1.00	3.00	3.00	3.00	3.00	3.00
Maximum	4.00	4.00	5.00	5.00	5.00	5.00	5.00
Median	1.00	1.00	5.00	5.00	5.00	5.00	5.00
Range	3.00	3.00	2.00	2.00	2.00	2.00	2.00

	Gustavo Ferrer MD {Chron Cough}	Jinesh Mehta MD {Sedation}	Raed A Dweik MD {Asthma}	Eduardo Oliveira MD {Broncho} Bias	Charlie Strange MD {COPD} Bias	Franck Rahaghi MD {AATD} Bias	Ioana Preston MD {PAH} Bias
Mean	4.85	4.71	4.81	4.88	4.93	4.90	4.89
Variance	0.18	0.36	0.19	0.12	0.07	0.11	0.12
Standard Deviation	0.42	0.60	0.44	0.35	0.26	0.33	0.34
Standard Error	0.04	0.06	0.04	0.03	0.03	0.03	0.03
Minimum	3.00	2.00	3.00	3.00	4.00	3.00	3.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Range	2.00	3.00	2.00	2.00	1.00	2.00	2.00

	Robert Kaner MD {IPF} Bias	Gustavo Ferrer MD {Chron Cough} Bias	Jinesh Mehta MD {Sedation} Bias	Raed A Dweik MD {Asthma} Bias	Reasons for Participating	Future CE Activities
Mean	4.88	4.89	4.85	4.90	-	1.48
Variance	0.12	0.12	0.17	0.09	-	0.40
Standard Deviation	0.35	0.34	0.41	0.30	-	0.63
Standard Error	0.03	0.04	0.04	0.03	-	0.06
Minimum	3.00	3.00	3.00	4.00	-	1.00
Maximum	5.00	5.00	5.00	5.00	-	3.00
Median	5.00	5.00	5.00	5.00	-	1.00
Range	2.00	2.00	2.00	1.00	-	2.00